VTP-50469

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (7)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MEN1 G326D1
Revumenib + VTP-50469

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

MEN1 G326R1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	B	Supports Resistance	3	submitted	EID12734 Tumor DNA sequencing identified the MEN1 G326R (aka G331R) variant in one patient (#2, who also had a MEN1 M322I) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting fiv… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 M322I1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	B	Supports Resistance	3	submitted	EID12730 Tumor DNA sequencing identified the MEN1 M322I (aka M327I) variant in two patients (#5 & 6) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified … (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 M322V1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	D	Supports Resistance	2	submitted	EID12728 Tumor DNA sequencing identified the MEN1 M322V (aka M327V) variant in two patients (#1 & 3) with KMT2A rearranged AML on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targetin… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 S155C1
VTP-50469	Acute Leukemia	Predictive	D	Supports Resistance	2	submitted	EID12742 The S155C (S160C) variant was detected in one of 22 patient derived xenograft of several AML models after long term treatment with the MENIN inhibitor VTP-50469. In this graft, it co-occured with a M… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 S155T1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	C	Supports Resistance	2	submitted	EID12741 Tumor DNA sequencing identified the MEN1 S155T (aka S160T) variant in one patient (#3, who also had a MEN1 M322V) on the AUGMENT-101 phase 1 trial of Revumenib. The S155T variant was NOT detected in a… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 T344M1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	B	Supports Resistance	4	submitted	EID12733 Tumor DNA sequencing identified the MEN1 T344M (aka T349M) variant in one patient (#4) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified a tot… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic